BioCentury | Jan 28, 2020
Emerging Company Profile

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BC Innovations | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
BC Extra | Apr 22, 2019
Company News

Variant expands pipeline with InflamaCore inflammasome deal

InflamaCore granted Variant exclusive, worldwide rights to develop and commercialize IC 100 and related products to treat inflammatory diseases. Variant Pharmaceuticals Inc. (Weston, Fla.) also gained rights to develop companion diagnostics for the mAb targeting...
BC Innovations | Apr 12, 2019
Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
BC Week In Review | Oct 26, 2018
Clinical News

Castle Creek discontinues Phase II of epidermolysis bullosa compound

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet...
BC Innovations | Oct 18, 2018
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting CASP1 could help treat AD. In primary human neurons overexpressing APP, a tool compound CASP1 inhibitor decreased axon degeneration compared with no treatment. In...
BC Innovations | Aug 30, 2018
Translation in Brief

Turning off the inflammasome

In a July Nature paper , a team from the University of California San Diego identified CMPK2 as a potential target for inflammatory diseases involving NLRP3 inflammasomes and may launch a spinout to develop the findings....
BC Innovations | Jul 19, 2018
Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those...
BC Innovations | Jun 28, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting CASP1 could help treat MS. In patient postmortem brain tissue samples, levels of CASP1 were higher than in samples from unaffected subjects. In the...
BC Week In Review | Jul 14, 2017
Clinical News

Castle Creek begins Phase II/III of topical diacerein to treat epidermolysis bullosa simplex

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test...
Items per page:
1 - 10 of 38